Copy Link Print Information

Gap 27

7 Cited Publications
Customer Review

Based on 7 publication(s) in Google Scholar

Gap 27, a synthetic connexin43 mimetic peptide, is a gap junction inhibitor. Gap 27 possesses conserved sequence homology to a portion of the second extracellular loop leading into the fourth transmembrane connexin segment.

For research use only. We do not sell to patients.

  • Purity: 99.90%
  • CAS No.: 198284-64-9
  • Formula: C60H101N15O17
  • Molecular Weight:1304.53
  • Storage:

    Sealed storage, away from moisture.

    Powder   -80°C, 2 years , -20°C, 1 year

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

  • Gap 27 Chemical Structure
    Gap 27 Chemical Structure
  • Experimental Validation Results for Gap 27
  • Experimental Validation Results for Gap 27
  • Experimental Validation Results for Gap 27
  • Experimental Validation Results for Gap 27
  • Experimental Validation Results for Gap 27
  • Experimental Validation Results for Gap 27
  • Experimental Validation Results for Gap 27
  • Experimental Validation Results for Gap 27
  • Experimental Validation Results for Gap 27
CAS No.: 198284-64-9
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Protocol
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Gap 27

More
Customer Validation & Images
WBIn Vivo Efficacy StudyIFRT-PCR
  • WB
  • In Vivo Efficacy Study
  • IF
  • WB
  • In Vivo Efficacy Study
  • WB
  • RT-PCR
  • IF
  • WB
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Gap 27 Chemical Structure
    Gap 27 Chemical Structure
    1/16
  • 1/16

    Gap 27 purchased from MedChemExpress. Usage Cited in: Brain Behav Immun. 2026 Jan:131:106176. [Abstract]

    Customer Validation
     Gap 27 (1 mg/mL; 1 μL bilaterally microinjected into the medial prefrontal cortex (mPFC) over 10 min) significantly decreased Cx43 expression levels in the mPFC of mice, whereas RBD administration did not further alter Cx43 expression.

  • 1/16

    Gap 27 purchased from MedChemExpress. Usage Cited in: Brain Behav Immun. 2026 Jan:131:106176. [Abstract]

    Customer Validation
     Gap 27 (1 mg/mL; 1 μL bilaterally microinjected into the medial prefrontal cortex (mPFC) over 10 min) pretreatment markedly decreased sucrose preference in the sucrose preference test (SPT), increased immobility time in the forced swim test (FST), reduced locomotor activity in the open field test (OFT), and prolonged immobility time in the tail suspension test (TST) compared to control mice.

  • 1/16

    Gap 27 purchased from MedChemExpress. Usage Cited in: Brain Behav Immun. 2026 Jan:131:106176. [Abstract]

    Customer Validation
     Gap 27 (1 mg/mL; 1 μL bilaterally microinjected into the medial prefrontal cortex (mPFC) over 10 min) significantly reduced the proportion of Cx43 fluorescent spots at the interstitial junctions of astrocytes in the medial prefrontal cortex of mice, while RBD treatment had no such effect.

  • 1/16

    Gap 27 purchased from MedChemExpress. Usage Cited in: Brain Behav Immun. 2026 Jan:131:106176. [Abstract]

    Customer Validation
     Representative immunoblots of the cGAS-STING signaling pathway in primary astrocytes in the Vehicle, Gap 27 (200 μM; 24 h), and Gap 27 + RBD (10 nM; 24 h) groups were shown. The results showed that Gap 27 treatment significantly increased protein levels of cGAS and activated components of the cGAS-STING pathway, including p-STING/STING, p-TBK1/TBK1, and p-IRF3/IRF3. Notably, these protein levels remained unchanged when RBD was added to Gap 27-treated astrocytes.

  • 1/16

    Gap 27 purchased from MedChemExpress. Usage Cited in: Cell Biol Toxicol. 2023 Jun;39(3):679-702. [Abstract]

    Customer Validation
     The PWT and PWL of mice after intrathecal injection of Gap27 (14.4, 43.2, 144 nM; 10 μL) for 2 h, compared with the VCR group at the same point in time, n = 8 mice/group. The results indicated that, compared with the VCR group at the same time point, intrathecal injections of Gap27 dose-dependently reversed mechanical allodynia and heat hyperalgesia at 2 h after treatment.

  • 1/16

    Gap 27 purchased from MedChemExpress. Usage Cited in: Cell Biol Toxicol. 2023 Jun;39(3):679-702. [Abstract]

    Customer Validation
     Western blotting and quantitative analysis of Cx43 protein expression in spinal cord of mice treated with Gap 27 (14.4, 43.2, 144 nM; 10 μL; intrathecal injection), n = 3 mice/group. The results suggested that the protein levels of Cx43 declined remarkably after the first intrathecal injection of Gap 27 for 36 h.

  • 1/16

    Gap 27 purchased from MedChemExpress. Usage Cited in: Cell Biol Toxicol. 2023 Jun;39(3):679-702. [Abstract]

    Customer Validation
     qRT-PCR analysis of spinal cord Cx43 mRNA level after Gap 27 (14.4, 43.2, 144 nM; 10 μL; intrathecal injection) injection, n = 4 mice/group. The results suggested that the mRNA levels of Cx43 declined remarkably after the first intrathecal injection of Gap27 for 36 h.

  • 1/16

    Gap 27 purchased from MedChemExpress. Usage Cited in: Cell Biol Toxicol. 2023 Jun;39(3):679-702. [Abstract]

    Customer Validation
     Immunofluorescence images of Cx43 intensity in the astrocyte cultures following treatment with Gap 27 (30 μM) for 24 h, n = 3 cultures/group. The results showed that VCR treatment (3 nM, 24 h) evoked a pronounced upregulation in the fluorescence intensity of astrocytes Cx43 and this was reversed by Gap 27 (30 μM).

  • 1/16

    Gap 27 purchased from MedChemExpress. Usage Cited in: Cell Biol Toxicol. 2023 Jun;39(3):679-702. [Abstract]

    Customer Validation
     The Western blotting analysis proved that the increase in Cx43 expression induced by VCR was reduced by 41.2% in astrocyte cultures treated with Gap 27 (30 μM) for 24 h.

  • Gap 27